Wasatch Advisors LP Sells 973,341 Shares of Certara, Inc. $CERT

Wasatch Advisors LP lowered its position in shares of Certara, Inc. (NASDAQ:CERT) by 18.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,298,825 shares of the company’s stock after selling 973,341 shares during the quarter. Wasatch Advisors LP owned 2.76% of Certara worth $28,157,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Granite Investment Partners LLC bought a new stake in shares of Certara in the 1st quarter valued at about $2,130,000. UBS Group AG lifted its stake in Certara by 50.7% in the 4th quarter. UBS Group AG now owns 2,489,603 shares of the company’s stock valued at $21,933,000 after purchasing an additional 837,648 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Certara by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock worth $48,806,000 after purchasing an additional 175,024 shares during the period. Quantinno Capital Management LP grew its holdings in Certara by 412.5% during the first quarter. Quantinno Capital Management LP now owns 988,990 shares of the company’s stock worth $5,637,000 after purchasing an additional 796,007 shares during the period. Finally, Kopion Asset Management LLC increased its position in Certara by 44.2% during the second quarter. Kopion Asset Management LLC now owns 1,858,539 shares of the company’s stock worth $12,173,000 after buying an additional 570,087 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on CERT shares. Weiss Ratings upgraded Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. BMO Capital Markets reduced their target price on Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Tuesday, May 12th. Stephens decreased their target price on Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Morgan Stanley dropped their price target on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, Barclays raised their price target on Certara from $6.50 to $7.50 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Certara currently has a consensus rating of “Hold” and an average price target of $8.28.

Certara Stock Down 1.5%

Shares of CERT opened at $8.01 on Thursday. The firm has a market cap of $1.22 billion, a P/E ratio of -17.80 and a beta of 1.44. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. Certara, Inc. has a 52 week low of $4.45 and a 52 week high of $13.88. The firm’s 50-day simple moving average is $6.70 and its 200 day simple moving average is $6.50.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The company had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. During the same quarter last year, the business earned $0.07 earnings per share. The company’s revenue was down 10.8% on a year-over-year basis. On average, analysts forecast that Certara, Inc. will post 0.22 earnings per share for the current year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.